{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:41:35Z","timestamp":1774280495854,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s13760-020-01556-3","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T02:40:10Z","timestamp":1610592010000},"page":"1131-1140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ophthalmologic manifestations in myasthenia gravis: presentation and prognosis"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8520-670X","authenticated-orcid":false,"given":"Onur","family":"Akan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6647-4485","authenticated-orcid":false,"given":"Leyla","family":"Baysal-Kirac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"1556_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"1556_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ncl.2016.08.008","volume":"35","author":"SV Smith","year":"2017","unstructured":"Smith SV, Lee AG (2017) Update on ocular myasthenia gravis. Neurol Clin 35:115\u2013123. https:\/\/doi.org\/10.1016\/j.ncl.2016.08.008","journal-title":"Neurol Clin"},{"key":"1556_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1749-6632.2012.06780.x","volume":"1275","author":"M Benatar","year":"2012","unstructured":"Benatar M, Sanders DB, Wolfe GI, McDermott MP, Tawil R (2012) Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial. Ann N Y Acad Sci 1275:17\u201322. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06780.x","journal-title":"Ann N Y Acad Sci"},{"key":"1556_CR4","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","volume":"122","author":"L Nagia","year":"2015","unstructured":"Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER (2015) Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology 122:1517\u20131521. https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.010","journal-title":"Ophthalmology"},{"key":"1556_CR5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/mus.25983","volume":"57","author":"KY Teo","year":"2018","unstructured":"Teo KY, Tow SL, Haaland B, Gosavi TD, Jing-Liang L, Yew Long LO, Milea D (2018) Low conversion rate of ocular to generalized myasthenia gravis in Singapore. Muscle Nerve 57:756\u2013760. https:\/\/doi.org\/10.1002\/mus.25983","journal-title":"Muscle Nerve"},{"key":"1556_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","volume":"205","author":"TM Hendricks","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, Chen JJ (2019) Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol 205:99\u2013105. https:\/\/doi.org\/10.1016\/j.ajo.2019.04.017","journal-title":"Am J Ophthalmol"},{"key":"1556_CR7","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00415-018-9056-8","volume":"265","author":"F Li","year":"2018","unstructured":"Li F, Hotter B, Swierzy M, Ismail M, Meisel A, R\u00fcckert JC (2018) Generalization after ocular onset in myasthenia gravis: a case series in Germany. J Neurol 265:2773\u20132782. https:\/\/doi.org\/10.1007\/s00415-018-9056-8","journal-title":"J Neurol"},{"key":"1556_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/00041327-200109000-00010","volume":"21","author":"F Bandini","year":"2001","unstructured":"Bandini F, Faga D, Simonetti S (2001) Ocular myasthenia mimicking a one-and-a-half syndrome. J Neuroophthalmol 21:210\u2013211. https:\/\/doi.org\/10.1097\/00041327-200109000-00010","journal-title":"J Neuroophthalmol"},{"key":"1556_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3928\/0191-3913-20020101-13","volume":"39","author":"JC Das","year":"2002","unstructured":"Das JC, Chaudhuri Z, Bhomaj S, Sharma P, Aggarwal M (2002) Ocular myasthenia presenting as progressive external ophthalmoplegia. J Pediatr Ophthalmol Strabismus 39:52\u201354","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"1556_CR10","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/bjo.2004.063404","volume":"89","author":"MJ Kupersmith","year":"2005","unstructured":"Kupersmith MJ, Ying G (2005) Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol 89:1330\u20131334. https:\/\/doi.org\/10.1136\/bjo.2004.063404","journal-title":"Br J Ophthalmol"},{"key":"1556_CR11","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1212\/01.wnl.0000263481.14289.90","volume":"68","author":"Benatar M, Kaminski HJ, Quality Standards Subcommittee of the American Academy of Neurology","year":"2007","unstructured":"Benatar M, Kaminski HJ, Quality Standards Subcommittee of the American Academy of Neurology (2007) Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 68:2144\u20132149. https:\/\/doi.org\/10.1212\/01.wnl.0000263481.14289.90","journal-title":"Neurology"},{"key":"1556_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10072-009-0106-y","volume":"30","author":"AA Argyriou","year":"2009","unstructured":"Argyriou AA, Karanasios P, Potsios C, Makridou A, Doukas V, Koukopoulou I, Makris N (2009) Myasthenia gravis initially presenting with pseudo-internuclear ophthalmoplegia. Neurol Sci 30:387\u2013388. https:\/\/doi.org\/10.1007\/s10072-009-0106-y","journal-title":"Neurol Sci"},{"key":"1556_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/15569520701830992","volume":"16","author":"M Cleary","year":"2008","unstructured":"Cleary M, Williams GJ, Metcalfe RA (2008) The pattern of extra-ocular muscle involvement in ocular myasthenia. Strabismus 16:11\u201318. https:\/\/doi.org\/10.1080\/15569520701830992","journal-title":"Strabismus"},{"key":"1556_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jocn.2015.08.026","volume":"25","author":"Y Almog","year":"2016","unstructured":"Almog Y, Ben-David M, Nemet AY (2016) Inferior oblique muscle paresis as a sign of myasthenia gravis. J Clin Neurosci 25:50\u201353. https:\/\/doi.org\/10.1016\/j.jocn.2015.08.026","journal-title":"J Clin Neurosci"},{"key":"1556_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/jnnp-2017-315782","volume":"88","author":"A Evoli","year":"2017","unstructured":"Evoli A, Alboini PE, Iorio R, Damato V, Bartoccioni E (2017) Pattern of ocular involvement in myasthenia gravis with MuSK antibodies. J Neurol Neurosurg Psychiatry 88:761\u2013763. https:\/\/doi.org\/10.1136\/jnnp-2017-315782","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1556_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ncl.2018.01.003","volume":"36","author":"M Al-Haidar","year":"2018","unstructured":"Al-Haidar M, Benatar M, Kaminski HJ (2018) Ocular Myasthenia. Neurol Clin 36:241\u2013251. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.003","journal-title":"Neurol Clin"},{"key":"1556_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/nyas.13471","volume":"1412","author":"JM Heckmann","year":"2018","unstructured":"Heckmann JM, Nel M (2018) A unique subphenotype of myasthenia gravis. Ann N Y Acad Sci 1412:14\u201320. https:\/\/doi.org\/10.1111\/nyas.13471","journal-title":"Ann N Y Acad Sci"},{"key":"1556_CR18","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/mus.26172","volume":"58","author":"TA Europa","year":"2018","unstructured":"Europa TA, Nel M, Heckmann JM (2018) Myasthenic ophthalmoparesis: time to resolution after initiating immune therapies. Muscle Nerve 58:542\u2013549. https:\/\/doi.org\/10.1002\/mus.26172","journal-title":"Muscle Nerve"},{"key":"1556_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1749-6632.2012.06775.x","volume":"1274","author":"E St\u00e5lberg","year":"2012","unstructured":"St\u00e5lberg E (2012) Jitter analysis with concentric needle electrodes. Ann N Y Acad Sci 1274:77\u201385. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06775.x","journal-title":"Ann N Y Acad Sci"},{"key":"1556_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.24165\/jns.10168.17","volume":"34","author":"NG Sirin","year":"2017","unstructured":"Sirin NG, Orhan EK, Durmus H, Oflazer P, Parman Y, Oge AE, Deymeer F, Baslo MB (2017) Jitter measurement using a concentric Needle in 133 patients with myasthenia gravis: a retrospective analysis. Neurol Sci Neurophysiol 34:207\u2013214. https:\/\/doi.org\/10.24165\/jns.10168.17","journal-title":"Neurol Sci Neurophysiol"},{"key":"1556_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16","journal-title":"Neurology"},{"key":"1556_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"key":"1556_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s004150050059","volume":"244","author":"R Beekman","year":"1997","unstructured":"Beekman R, Kuks JB, Oosterhuis HJ (1997) Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol 244:112\u2013118. https:\/\/doi.org\/10.1007\/s004150050059","journal-title":"J Neurol"},{"key":"1556_CR24","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/S0161-6420(03)00460-3","volume":"110","author":"JH Kim","year":"2003","unstructured":"Kim JH, Hwang JM, Hwang YS, Kim KJ, Chae J (2003) Childhood ocular myasthenia gravis. Ophthalmology 110:1458\u20131462. https:\/\/doi.org\/10.1016\/S0161-6420(03)00460-3","journal-title":"Ophthalmology"},{"key":"1556_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/BF01675867","volume":"52","author":"HJ Oosterhuis","year":"1982","unstructured":"Oosterhuis HJ (1982) The ocular signs and symptoms of myasthenia gravis. Doc Ophthalmol 52:363\u2013378","journal-title":"Doc Ophthalmol"},{"key":"1556_CR26","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/jnnp.2005.075812","volume":"77","author":"DL Bennett","year":"2006","unstructured":"Bennett DL, Mills KR, Riordan-Eva P, Barnes PR, Rose MR (2006) Anti-MuSK antibodies in a case of ocular myasthenia gravis. J Neurol Neurosurg Psychiatry 77:564\u2013565. https:\/\/doi.org\/10.1136\/jnnp.2005.075812","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1556_CR27","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/00041327-199612000-00012","volume":"16","author":"K Okamoto","year":"1996","unstructured":"Okamoto K, Ito J, Tokiguchi S, Furusawa T (1996) Atrophy of bilateral extraocular muscles. CT and clinical features of seven patients. J Neuroophthalmol 16:286\u2013288","journal-title":"J Neuroophthalmol"},{"key":"1556_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4236\/ojoph.2014.44019","volume":"4","author":"SM Gratton","year":"2014","unstructured":"Gratton SM, Herro A, Bermudez-Magner JA, Guy J (2014) Atrophy and fibrosis of extra-ocular muscles in anti-acetylcholine receptor antibody myasthenia gravis. Open J Ophthalmol 4:117. https:\/\/doi.org\/10.4236\/ojoph.2014.44019","journal-title":"Open J Ophthalmol"},{"key":"1556_CR29","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/WNO.0000000000000534","volume":"37","author":"RM Rautenbach","year":"2017","unstructured":"Rautenbach RM, Pillay K, Murray ADN, Heckmann JM (2017) Extraocular muscle findings in myasthenia gravis associated treatment-resistant ophthalmoplegia: a case report. J Neuroophthalmol 37:414\u2013417. https:\/\/doi.org\/10.1097\/WNO.0000000000000534","journal-title":"J Neuroophthalmol"},{"key":"1556_CR30","doi-asserted-by":"publisher","first-page":"e55611","DOI":"10.1371\/journal.pone.0055611","volume":"8","author":"R Liu","year":"2013","unstructured":"Liu R, Xu H, Wang G, Li J, Gou L, Zhang L, Miao J, Li Z (2013) Extraocular muscle characteristics related to myasthenia gravis susceptibility. PLoS ONE 8:e55611. https:\/\/doi.org\/10.1371\/journal.pone.0055611","journal-title":"PLoS ONE"},{"key":"1556_CR31","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.nmd.2017.06.009","volume":"27","author":"M Nel","year":"2017","unstructured":"Nel M, Jalali Sefid Dashti M, Gamieldien J, Heckmann JM (2017) Exome sequencing identifies targets in the treatment-resistant ophthalmoplegic subphenotype of myasthenia gravis. Neuromuscul Disord 27:816\u2013825. https:\/\/doi.org\/10.1016\/j.nmd.2017.06.009","journal-title":"Neuromuscul Disord"},{"key":"1556_CR32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/MAJ.0b013e318219bcf6","volume":"342","author":"F Tateno","year":"2011","unstructured":"Tateno F, Sakakibara R, Kishi M, Ogawa E (2011) Hashimoto\u2019s ophthalmopathy. Am J Med Sci 342:83\u201385. https:\/\/doi.org\/10.1097\/MAJ.0b013e318219bcf6","journal-title":"Am J Med Sci"},{"key":"1556_CR33","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/mus.21555","volume":"41","author":"JA Allen","year":"2010","unstructured":"Allen JA, Scala S, Jones HR (2010) Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve 41:379\u2013384. https:\/\/doi.org\/10.1002\/mus.21555","journal-title":"Muscle Nerve"},{"issue":"11","key":"1556_CR34","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","volume":"94","author":"E Cort\u00e9s-Vicente","year":"2020","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Segovia S, Paradas C, Casasnovas C, Guerrero-Sola A, Pardo J, Ramos-Fransi A, Sevilla T, L\u00f3pez de Munain A, G\u00f3mez MT, Jeric\u00f3 I, Guti\u00e9rrez-Guti\u00e9rrez G, Pelayo-Negro AL, Mart\u00edn MA, Mendoza MD, Mor\u00eds G, Rojas-Garcia R, D\u00edaz-Manera J, Querol L, Gallardo E, V\u00e9lez B, Albert\u00ed MA, Gal\u00e1n L, Garc\u00eda-Sobrino T, Mart\u00ednez-Pi\u00f1eiro A, Lozano-Veintimilla A, Fern\u00e1ndez-Torr\u00f3n R, Cano-Abascal \u00c1, Illa I (2020) Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology 94(11):e1171\u2013e1180","journal-title":"Neurology"},{"key":"1556_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000487132","volume":"79","author":"F Aguirre","year":"2018","unstructured":"Aguirre F, Villa AM (2018) Prognosis of ocular myasthenia gravis in an Argentinian population. Eur Neurol 79:113\u2013117. https:\/\/doi.org\/10.1159\/000487132","journal-title":"Eur Neurol"},{"issue":"1","key":"1556_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","volume":"17","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang Y, He M (2017) Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol 17(1):77. https:\/\/doi.org\/10.1186\/s12883-017-0857-7","journal-title":"BMC Neurol"},{"key":"1556_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jns.2008.05.023","volume":"273","author":"Hong YH, Kwon SB, Kim BJ, Kim BJ, Kim SH, Kim JK, Park KS, Park KJ, Sung JJ, Sohn EH, Lee YB, Jeong D, Joo IS, Choi BO, Choi YC; Korean Research Group for Neuromuscular Diseases","year":"2008","unstructured":"Hong YH, Kwon SB, Kim BJ, Kim BJ, Kim SH, Kim JK, Park KS, Park KJ, Sung JJ, Sohn EH, Lee YB, Jeong D, Joo IS, Choi BO, Choi YC; Korean Research Group for Neuromuscular Diseases (2008) Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci 273:10\u201314. https:\/\/doi.org\/10.1016\/j.jns.2008.05.023","journal-title":"J Neurol Sci"},{"key":"1556_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","volume":"217","author":"NT Monsul","year":"2004","unstructured":"Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM (2004) The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 217:131\u2013133. https:\/\/doi.org\/10.1016\/j.jns.2003.08.017","journal-title":"J Neurol Sci"},{"key":"1556_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s13760-019-01252-x","volume":"120","author":"S Yildiz Celik","year":"2020","unstructured":"Yildiz Celik S, Durmus H, Yilmaz V, Saruhan Direskeneli G, Gulsen Parman Y, Serdaroglu Oflazer P, Deymeer F (2020) Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome. Acta Neurol Belg 120:133\u2013140. https:\/\/doi.org\/10.1007\/s13760-019-01252-x","journal-title":"Acta Neurol Belg"},{"key":"1556_CR40","doi-asserted-by":"publisher","first-page":"474512","DOI":"10.4061\/2011\/474512","volume":"2011","author":"F Romi","year":"2011","unstructured":"Romi F (2011) Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis 2011:474512. https:\/\/doi.org\/10.4061\/2011\/474512","journal-title":"Autoimmune Dis"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01556-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-020-01556-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01556-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T12:41:28Z","timestamp":1631709688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-020-01556-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1556"],"URL":"https:\/\/doi.org\/10.1007\/s13760-020-01556-3","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,4]]},"assertion":[{"value":"16 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author(s) declared no conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}